Prostate cancer Cancer Malignant neoplasm of prostate
Conditions
Interventions
1. Sample Collection: Peripheral blood samples will be collected into tubes containing EDTA with the sole precaution of discarding the first milliliters to avoid possible contamination of samples with
http://microrna.sanger.ac.uk/
http://www.ma.uniheidelberg.de/apps/zmf/argonaute/interface/. These pages are being updated constantly and are very useful for finding potential markers of miRNA (microRNA) that may be over-expressed
Sponsors
The Foundation for Research in Urology [Fundación para la Investigación en Urología (FIU)] (Spain)
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Patients with pathological diagnosis confirmed of localized, locally advanced or metastatic prostate cancer according to the TNM (tumor, lymph nodes, metastasis) classification, NCCN (National Comprehensive Cancer Network), during the period of study 2. Older than 18 years 3. Patients with signed informed consent
Exclusion criteria
Exclusion criteria: 1. Patients with a history of epithelial cancer, except skin carcinoma correctly treated 2. Patients who are receiving systemic cancer treatment 3. Thrombocytopenia less than 20,000 /ml or coagulopathies not medically controlled
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Look at the possible relationship between the expression profiles of the microRNAs and the ability of prediction groups risk in prostate cancer, in patients who have not suffered therapeutic maneuvers 2. Establish a panel of circulating microRNAs useful in the diagnosis and prognosis of prostate cancer | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. We will explore different patterns of microRNAs to estimate the response to the local therapy or hormonal manipulation including in the context of hormone-refractory patients 2. Identification of potential target genes of the microRNAs with significance by predictions of interaction through the mirbase database, TargetScan and the software's Crosslink and Pathway Studio (Ariadne Genomics) | — |
Countries
Spain
Outcome results
None listed